+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Relapsing Refractory Multiple Myeloma - Epidemiology Forecast to 2028

  • ID: 4845161
  • Report
  • September 2019
  • Region: Global
  • 80 pages
  • DelveInsight
1 of 2
‘Relapsing Refractory Multiple Myeloma- Epidemiology Forecast to 2028' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Relapsing Refractory Multiple Myeloma in Asia (China and Taiwan), Middle East (Saudi Arabia and UAE), Eastern Europe (Russia and Turkey) and LATAM (Mexico, Brazil, Argentina and Columbia).

Geography Covered
  • Asia (China and Taiwan)
  • Middle East (Saudi Arabia and UAE)
  • Eastern Europe (Russia and Turkey)
  • LATAM (Mexico, Brazil, Argentina and Columbia)
Study Period:2017-2028

Relapsing Refractory Multiple Myeloma - Disease Understanding

Multiple Myeloma (MM) is the second most incident hematological malignancy worldwide, with a median onset of 60 years. This incurable malignancy develops from an accumulation of terminally differentiated monoclonal plasma cells (PC) in the bone marrow. The mechanism of action of MM characterized by the unusual increase of monoclonal paraprotein leading to evidence of specific end-organ damage. The majority of patients with multiple myeloma (MM) will have an initial response to treatment with modern combination regimens. However, conventional therapy is not curative and most of these patients will ultimately progress. In addition, some patients will not respond to initial treatment (i.e., refractory disease). Relapsed or refractory MM is usually identified through routine monitoring with laboratory studies. The signs and symptoms of Multiple Myeloma include hypercalcemia, renal insufficiency, anemia, lytic bony lesions along with a monoclonal protein in the serum, increase in the number of clonal plasma cells in the bone marrow, etc.

The Relapsing Refractory Multiple Myeloma market report gives the thorough understanding of the Relapsing Refractory Multiple Myeloma by including details such as disease introduction, symptoms of multiple myeloma, molecular classification of Multiple Myeloma, stages of multiple myeloma, pathogenesis, pathophysiology, biomarkers for multiple myeloma, diagnosis and patient-related risk factors.

Relapsing Refractory Multiple Myeloma Epidemiology

The Relapsing Refractory Multiple Myeloma epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 10 major emerging markets (EM). The epidemiology data for Relapsing Refractory Multiple Myeloma are studied through all possible division to give a better understanding about the disease scenario in 10 EM. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Relapsing Refractory Multiple Myeloma Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology scenario of Relapsing Refractory Multiple Myeloma in 10 EM covering Asia (China and Taiwan), Middle East (Saudi Arabia and UAE), Eastern Europe (Russia and Turkey) and LATAM (Mexico, Brazil, Argentina and Columbia) from 2017-2028 for the following aspects:
  • Diagnosed Incident cases of Multiple Myeloma (MM)
  • Gender-specific Diagnosed Incidence of Multiple Myeloma (MM)
  • Diagnosed Incident Multiple Myeloma (MM) Population on Second Line of Treatment
  • Diagnosed Incident Multiple Myeloma (MM) Population on Third Line (and above) of Treatment
  • Total Diagnosed Incident RRMM cases
There are several potential research papers and studies evaluated in order to analyze the overall epidemiology trend in the emerging markets. Few are listed below:

Lu et al. conducted a study “Clinical features and treatment outcome in newly diagnosed Chinese patients with multiple myeloma: results of a multicenter analysis” with the aim to understand the clinical features and treatment outcome of Chinese patients with multiple myeloma (MM). As per the study, if the Japanese incidence of MM is applied to China, there would be an estimated 27,800 new cases (1.39 billion × 2 per 100,000) each year and a total of 200,000 cases in China. With the acceleration of the aging process in China, it is predicted that MM, with rapid growth in incidence, will become one of the more significant diseases that affect people's health in the country. It has also been reported that immigrants from Asia living in the USA have an increased incidence of MM compared with those living in Asia.

Hungria et al. suggest that Multiple Myeloma (MM) is a disorder characterized by abnormal clonal proliferation of plasmocytes in the bone marrow resulting in the production of monoclonal immunoglobulins associated with organic disorders. MM accounts for 1% of all neoplastic diseases and 13% of hematologic neoplasms as stated in “Guidelines on the diagnosis and management of multiple myeloma treatment: Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular Project guidelines: Associação Médica Brasileira - 2012.” In Brazil, there is no exact knowledge of the incidence of this disease.

Report Scope
  • The report covers detailed overview of Relapsing Refractory Multiple Myeloma explaining its causes, symptoms, and classification, pathophysiology, diagnosis and treatment patterns.
  • The report provides the insight about the historical and forecasted patient pool for 10 emerging markets covering Asia (China and Taiwan), Middle East (Saudi Arabia and UAE), Eastern Europe (Russia and Turkey) and LATAM (Mexico, Brazil, Argentina and Columbia).
  • The Report assesses the disease risk and burden and highlights the unmet needs of Relapsing Refractory Multiple Myeloma.
  • The Report helps to recognize the growth opportunities in 10 EM with respect to the patient population.
  • The report provides the segmentation of the disease epidemiology by type specific cases and severity specific cases of Relapsing Refractory Multiple Myeloma in 10 EM.
Key Strengths
  • 10 Year Forecast of Relapsing Refractory Multiple Myeloma epidemiology
  • 10 EM Coverage
  • Total Incident Cases of Relapsing Refractory Multiple Myeloma
  • Incident Cases according to segmentation
Key Assessments
  • Patient Segmentation
  • Disease Risk & Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population
Note: Product cover images may vary from those shown
2 of 2
1. Key Insights

2. Disease Background and Overview: Relapsing Refractory Multiple Myeloma (RRMM)
2.1. Introduction
2.2. Symptoms of multiple myeloma
2.3. Molecular Classification of Multiple Myeloma
2.4. Stages of Multiple Myeloma
2.5. Diagnosis of Multiple Myeloma
2.6. Pathogenesis of Multiple Myeloma
2.6.1. Molecular mechanisms underlying the progression of multiple myeloma
2.6.2. Molecular pathogenesis of multiple myeloma and its premalignant precursor
2.7. Pathophysiology of Multiple Myeloma
2.8. Biomarkers for Multiple Myeloma
2.8.1. Serum M-protein and light chains as biomarkers
2.8.2. Potential proteomic biomarkers
2.8.3. Cytogenetic biomarkers in multiple myeloma
2.9. Patient-related risk factors
2.10. Factors influencing the choice of therapy at relapse
2.11. Nutshell of Multiple Myeloma

3. Epidemiology and Patient Population: Key Findings
3.1. 10 EM Total Diagnosed Incident Patient Population of Relapsing Refractory Multiple Myeloma

4. Country Wise-Epidemiology of Relapsing Refractory Multiple Myeloma
4.1. East Asia: China and Taiwan
4.1.1. Assumptions and Rationale
4.2. China
4.2.1. Multiple Myeloma (MM) Diagnosed Incident cases in China
4.2.2. Multiple Myeloma (MM) Gender-specific Diagnosed Incidence in China
4.2.3. Multiple Myeloma (MM) Diagnosed Incident Population on Second Line of Treatment in China
4.2.4. Multiple Myeloma (MM) Diagnosed Incident Population on Third Line (and above) of Treatment in China
4.2.5. RRMM Total Diagnosed Incident cases in China
4.3. Taiwan
4.3.1. Multiple Myeloma (MM) Diagnosed Incident cases in Taiwan
4.3.2. Multiple Myeloma (MM) Gender-specific Diagnosed Incidence in Taiwan
4.3.3. Multiple Myeloma (MM) Diagnosed Incident Population on Second Line of Treatment in Taiwan
4.3.4. Multiple Myeloma (MM) Diagnosed Incident Population on Third Line (and above) of Treatment in Taiwan
4.3.5. RRMM Total Diagnosed Incident cases in Taiwan
4.4. Middle East: Saudi Arabia and United Arab Emirates
4.4.1. Assumptions and Rationale
4.5. Saudi Arabia
4.5.1. Multiple Myeloma (MM) Diagnosed Incident cases in Saudi Arabia
4.5.2. Multiple Myeloma (MM) Gender-specific Diagnosed Incidence in Saudi Arabia
4.5.3. Multiple Myeloma (MM) Diagnosed Incident Population on Second Line of Treatment in Saudi Arabia
4.5.4. Multiple Myeloma (MM) Diagnosed Incident Population on Third Line (and above) of Treatment in Saudi Arabia
4.5.5. RRMM Total Diagnosed Incident cases in Saudi Arabia
4.6. United Arab Emirates
4.6.1. Multiple Myeloma (MM) Diagnosed Incident cases in United Arab Emirates
4.6.2. Multiple Myeloma (MM) Gender-specific Diagnosed Incidence in United Arab Emirates
4.6.3. Multiple Myeloma (MM) Diagnosed Incident Population on Second Line of Treatment in United Arab Emirates
4.6.4. Multiple Myeloma (MM) Diagnosed Incident Population on Third Line (and above) of Treatment in United Arab Emirates
4.6.5. RRMM Total Diagnosed Incident cases in United Arab Emirates
4.7. Eastern Europe: Russia and Turkey
4.7.1. Assumptions and Rationale
4.8. Russia
4.8.1. Multiple Myeloma (MM) Diagnosed Incident cases in Russia
4.8.2. Multiple Myeloma (MM) Gender-specific Diagnosed Incidence in Russia
4.8.3. Multiple Myeloma (MM) Diagnosed Incident Population on Second Line of Treatment in Russia
4.8.4. Multiple Myeloma (MM) Diagnosed Incident Population on Third Line (and above) of Treatment in Russia
4.8.5. RRMM Total Diagnosed Incident cases in Russia
4.9. Turkey
4.9.1. Multiple Myeloma (MM) Diagnosed Incident cases in Turkey
4.9.2. Multiple Myeloma (MM) Gender-specific Diagnosed Incidence in Turkey
4.9.3. Multiple Myeloma (MM) Diagnosed Incident Population on Second Line of Treatment in Turkey
4.9.4. Multiple Myeloma (MM) Diagnosed Incident Population on Third Line (and above) of Treatment in Turkey
4.9.5. RRMM Total Diagnosed Incident cases in Turkey
4.10. Latin America (LATAM): Argentina, Brazil, Colombia, Mexico
4.10.1. Assumptions and Rationale
4.11. Mexico
4.11.1. Multiple Myeloma (MM) Diagnosed Incident cases in Mexico
4.11.2. Multiple Myeloma (MM) Gender-specific Diagnosed Incidence in Mexico
4.11.3. Multiple Myeloma (MM) Diagnosed Incident Population on Second Line of Treatment in Mexico
4.11.4. Multiple Myeloma (MM) Diagnosed Incident Population on Third Line (and above) of Treatment in Mexico
4.11.5. RRMM Total Diagnosed Incident cases in Mexico
4.12. Brazil
4.12.1. Multiple Myeloma (MM) Diagnosed Incident cases in Brazil
4.12.2. Multiple Myeloma (MM) Gender-specific Diagnosed Incidence in Brazil
4.12.3. Multiple Myeloma (MM) Diagnosed Incident Population on Second Line of Treatment in Brazil
4.12.4. Multiple Myeloma (MM) Diagnosed Incident Population on Third Line (and above) of Treatment in Brazil
4.12.5. RRMM Total Diagnosed Incident cases in Brazil
4.13. Argentina
4.13.1. Multiple Myeloma (MM) Diagnosed Incident cases in Argentina
4.13.2. Multiple Myeloma (MM) Gender-specific Diagnosed Incidence in Argentina
4.13.3. Multiple Myeloma (MM) Diagnosed Incident Population on Second Line of Treatment in Argentina
4.13.4. Multiple Myeloma (MM) Diagnosed Incident Population on Third Line (and above) of Treatment in Argentina
4.13.5. RRMM Total Diagnosed Incident cases in Argentina
4.14. Colombia
4.14.1. Multiple Myeloma (MM) Diagnosed Incident cases in Colombia
4.14.2. Multiple Myeloma (MM) Gender-specific Diagnosed Incidence in Colombia
4.14.3. Multiple Myeloma (MM) Diagnosed Incident Population on Second Line of Treatment in Colombia
4.14.4. Multiple Myeloma (MM) Diagnosed Incident Population on Third Line (and above) of Treatment in Colombia
4.14.5. RRMM Total Diagnosed Incident cases in Colombia

5. Market Drivers

6. Market Barriers

7. Appendix
7.1. Report Methodology

8. Capabilities

9. Disclaimer

10. About the Publisher
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll